- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1352792-74-5] Verinurad
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16733 |
| Brand: | MCE |
| CAS: | 1352792-74-5 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 348.42 |
| Molecular Formula | C20H16N2O2S |
| SMILES | CC(C)(SC1=C(C2=C3C=CC=CC3=C(C#N)C=C2)C=NC=C1)C(O)=O |
Summary
IC50 & Target
IC50: 25 nM (URAT1) [1]
In Vitro
Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC 50 of 25 nM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02317861 | AstraZeneca|Ardea Biosciences, Inc. |
Gout and Asymptomatic Hyperuricemia
|
December 2014 | Phase 1|Phase 2 |
| NCT01872832 | Ardea Biosciences, Inc. |
Gout
|
June 2013 | Phase 1 |
| NCT03118739 | AstraZeneca |
Hyperuricemia|Albuminuria|Type 2 Diabetes
|
May 18, 2017 | Phase 2 |
| NCT04256629 | AstraZeneca|Parexel |
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
|
March 3, 2020 | Phase 1 |
| NCT01883167 | Ardea Biosciences, Inc. |
Healthy
|
June 2013 | Phase 1 |
| NCT02246673 | Ardea Biosciences, Inc. |
Gout
|
October 2014 | Phase 2 |
| NCT03316131 | AstraZeneca|Contract Research Organization: USA|PAREXEL Early Phase Clinical Unit Baltimore|PAREXEL Early Phase Clinical Unit-Los Angeles|Clinical Laboratory: USA|Harbor Hospital Laboratory|GenX Laboratories Inc.|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA|Covance Bioanalytical Services, LLC |
Asymptomatic Hyperuricemia
|
October 25, 2017 | Phase 2 |
| NCT04327024 | AstraZeneca |
Heart Failure With Preserved Ejection Fraction (HFpEF)
|
May 19, 2020 | Phase 2 |
| NCT04024501 | AstraZeneca |
Chronic Kidney Disease
|
July 20, 2019 | Phase 1 |
| NCT02078219 | AstraZeneca|Ardea Biosciences, Inc. |
Gout and Hyperuricemia
|
January 5, 2014 | Phase 2 |
| NCT03990363 | AstraZeneca |
Chronic Kidney Disease
|
July 23, 2019 | Phase 2 |
| NCT04550234 | AstraZeneca|Parexel |
Chronic Kidney Disease
|
April 13, 2021 | Phase 1 |
| NCT04532918 | AstraZeneca|Parexel |
Chronic Kidney Disease
|
September 10, 2020 | Phase 1 |
| NCT02219516 | Ardea Biosciences, Inc. |
Gout
|
August 1, 2014 | Phase 1 |
| NCT02279641 | Ardea Biosciences, Inc. |
Gout
|
November 1, 2014 | Phase 1 |
| NCT02336594 | Ardea Biosciences, Inc. |
Gout
|
November 2014 | Phase 1 |
| NCT01927198 | Ardea Biosciences, Inc. |
Gout
|
August 2013 | Phase 2 |
| NCT02498652 | Ardea Biosciences, Inc. |
Gout
|
July 28, 2015 | Phase 2 |
| NCT02608710 | Ardea Biosciences, Inc. |
Gout
|
November 2015 | Phase 1 |
| NCT03836599 | AstraZeneca|Parexel |
Chronic Kidney Disease
|
January 16, 2019 | Phase 1 |
| NCT01910506 | Ardea Biosciences, Inc. |
Healthy
|
August 2013 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 287.01 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8701 mL | 14.3505 mL | 28.7010 mL |
| 5 mM | 0.5740 mL | 2.8701 mL | 5.7402 mL |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8701 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.